Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion

Kidney Diseases Clinical Trial

Official title: Reduction or Discontinuation of Calcineurine Inhibitors With Conversion to Everolimus-Based Immunosuppresion to Alleviate Chronic Allograft Nephropathy (CAN) in Kidney Transplant Recipients: A Prospective Randomized Study

Status Recruiting

Clinical Trial Summary

This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose.

The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance.

The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range.

Clinical Trial Description

This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose.

The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance.

The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range.

Patients will undergo the following baseline studies:

1. Doppler ultrasound to exclude any mechanical or a vascular problem.

2. A kidney biopsy to define the histological changes (degree of interstitial fibrosis, tubular and glomerular changes). The biopsies will be stained also for C4D and for fibrinogenic markers (TGF-beta, and collagen).

3. A 24-hour urine protein excretion and creatinine clearance

4. Echocardiography study

5. Carotid Ultrasound

The following parameters will be monitored every clinic visit throughout the study period:

1. SMA-12 including creatinine levels.

2. A complete blood count.

3. Cholesterol, HDL-cholesterol and triglyceride levels.

4. Blood pressure measurements (X2)

5. The number of blood pressure medications.

6. Cholesterol lowering medication requirement

7. Urine protein excretion (quantitative spot-test )

8. Protein amount in the urine

Study end points:

The data will be evaluated based on an intention to treat analysis and the following parameters will be compared between the two groups:

1. Creatinine levels and calculated creatinine clearance

2. Spot urine for Cr./protein ratio

3. 24-hr. protein excretion

4. Change in peak diastolic and mean arterial blood pressure

5. The number and dosage of blood pressure medications

6. Cholesterol, HDL and triglyceride levels

7. Proportion of patients on cholesterol lowering agents

8. Number and severity of biopsy proven acute rejection episodes

9. Incidence of biopsy proven chronic rejection. (depends on per protocol biopsy at end of study)

10. Patient and graft survival ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Kidney Diseases

• NCT number: NCT00443508
• Study type: Interventional
• Source: Rabin Medical Center
• Contact: Eytan Mor, Prof
• Phone: 00973 3 9376528
• Email: emor@clalit.org.il
• Status: Recruiting
• Phase: Phase 4
• Start date: February 2007
• Completion date: February 2010